Celltrion
Sustainability Report and Carbon Intensity Rankings
Is Celltrion doing their part?
Their DitchCarbon score is 48
Celltrion has a DitchCarbon Score of 48 out of 100, indicating a moderate level of sustainability in their operations. This score suggests that the company’s carbon intensity is relatively high, implying there is significant room for improvement in reducing emissions. To enhance their sustainability efforts, Celltrion would need to implement strategies to lower their carbon intensity and increase their DitchCarbon Score.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Celltrion is a company in the research and development sector, which has a carbon intensity ranking of very low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Unknown
High
Very high
Celltrion, based in South Korea, operates in a region with a specific carbon intensity rating. The sustainability of the company’s operations is influenced by South Korea’s national energy policies and carbon footprint.
Unlock 30+ emissions data points on Celltrion
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Celltrion
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
3.36%
...this company is doing 3.36% worse in emissions than the industry average.
Founded in 2002 and headquartered in Incheon, Republic of Korea, Celltrion, Inc. operates within the biopharmaceutical industry, specializing in the research and development of biosimilar monoclonal antibodies and novel drugs. The company has made significant strides in various therapeutic areas, including oncology and autoimmune diseases. Celltrion’s notable achievements include the EMA approval of Remsima, marking a pioneering step in the biosimilar market.
emission intelligence's platform recommendations for Celltrion
Celltrion should undertake a thorough inventory of all Scope 1 emissions sources to identify and quantify direct greenhouse gas emissions from their operations.
Bad news, Celltrion hasn't committed to SBTi goals yet
Celltrion has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company is still in the process of defining clear, science-based emissions reduction targets to align with global efforts to mitigate climate change.
Not participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.